According to Times of India, Novartis obtained favourable court orders restraining five Ahmedabad-based pharma companies from manufacturing its patented drug for diabetes, Vildagliptin. Further, citing validity of its patent till 09 December 2019, Novartis moved the commercial court in Vadodara to ensure that four other companies do not get into production of the drug. It is reported that Novartis approached the Court after obtaining the requisite information from the State Government.
Related Posts
Only ‘Disclosed’ if ‘Identified’: IPAB Quashes Ceritinib Patent Revocation
Revocation of Novartis’ Ceritinib Patent Stayed: Unraveling the IPAB Order
No Reasons Why : Questioning Delhi HC’s Interim Injunction against Sun Pharma in Novartis’ Nilotinib Patent Infringement Suit
It is “Covered”, Yes, but is it “Disclosed”? Delhi HC Gives a Huge Shot in the Arm to Pharma Patents in India
Transborder Prosecution History Estoppel in Patent Litigation?
2 comments.
Am I missing something, or is “aggressive patent strategy” being used to mean “enforcing its patent”? Seems a bit much.
Kind of agree with you, Mr. Sadly No.
However, I believe that the bent was more in the context of patent expiring in 15 months from now … I am sure Novartis is (rightly so) going to not let any non-licensed player before Dec 2019.